Reduced antibody activity against SARS-CoV-2 B.1.617.2 Delta virus in serum of mRNA-vaccinated patients receiving TNF-α inhibitors
Preprint
- 29 September 2021
- preprint
- research article
- Published by Cold Spring Harbor Laboratory
Abstract
SUMMARY: Although vaccines effectively prevent COVID-19 in healthy individuals, they appear less immunogenic in individuals with chronic inflammatory diseases (CID) and/or under chronic immunosuppression, and there is uncertainty of their activity against emerging variants of concern in this population. Here, we assessed a cohort of 74 CID patients treated as monotherapy with chronic immunosuppressive drugs for functional antibody responses in serum against historical and variant SARS-CoV-2 viruses after immunization with Pfizer mRNA BNT162b2 vaccine. Longitudinal analysis showed the greatest reductions in neutralizing antibodies and Fc effector function capacity in individuals treated with TNF-α inhibitors, and this pattern appeared worse against the B.1.617.2 Delta virus. Within five months of vaccination, serum neutralizing titers of the majority of CID patients fell below the presumed threshold correlate for antibody-mediated protection. Thus, further vaccine boosting or administration of long-acting prophylaxis (e.g., monoclonal antibodies) likely will be required to prevent SARS-CoV-2 infection in this susceptible population.Keywords
This publication has 71 references indexed in Scilit:
- Antibody Response to Hepatitis B Virus Vaccine is Impaired in Patients With Inflammatory Bowel Disease on Infliximab TherapyInflammatory Bowel Diseases, 2018
- Multiplexed Fc array for evaluation of antigen-specific antibody effector profilesJournal of Immunological Methods, 2017
- Janeway's ImmunobiologyPublished by Taylor & Francis Ltd ,2016
- Efficacy of Hepatitis A Vaccination and Factors Impacting on Seroconversion in Patients with Inflammatory Bowel DiseaseInflammatory Bowel Diseases, 2014
- Effect of Methotrexate, Anti–Tumor Necrosis Factor α, and Rituximab on the Immune Response to Influenza and Pneumococcal Vaccines in Patients With Rheumatoid Arthritis: A Systematic Review and Meta‐AnalysisArthritis Care & Research, 2013
- Immune response to influenza A/H1N1 vaccine in inflammatory bowel disease patients treated with anti TNF-α agents: Effects of combined therapy with immunosuppressantsJournal of Crohn's and Colitis, 2013
- High-throughput, multiplexed IgG subclassing of antigen-specific antibodies from clinical samplesJournal of Immunological Methods, 2012
- Effects of immunosuppression on immune response to pneumococcal vaccine in inflammatory bowel disease: A prospective study*Inflammatory Bowel Diseases, 2012
- Serological response to the 2009 H1N1 influenza vaccination in patients with inflammatory bowel diseaseGut, 2011
- DEVELOPMENT AND MATURATION OF SECONDARY LYMPHOID TISSUESAnnual Review of Immunology, 1999